[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362630-105":59,"doc-detail-362630-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","relationship-between-menopausal-hormone-therapy-and-incidence-risk-of-breast-cancer-systematic-review-and-meta-analysis","Relationship between menopausal hormone therapy and incidence risk of breast cancer - systematic review and meta-analysis","","Menopausal hormone therapy (MHT) is widely used to relieve menopausal symptoms, yet evidence on how different formulations affect breast cancer risk remains mixed. This systematic review and meta-analysis synthesized eligible studies of MHT exposure and subsequent breast cancer incidence. Searches covered CNKI, Wanfang, PubMed, and Web of Science through August 2024 with screening and quality assessment by two reviewers following PRISMA guidance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/relationship-between-menopausal-hormone-therapy-and-incidence-risk-of-breast-cancer-systematic-review-and-meta-analysis/362630/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/relationship-between-menopausal-hormone-therapy-and-incidence-risk-of-breast-cancer-systematic-review-and-meta-analysis/362630.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main finding about MHT and breast cancer incidence risk?","Question",{"text":113,"@type":114},"Overall, MHT showed a significant but heterogeneous association with breast cancer risk (OR = 1.15, 95% CI: 1.09–1.22).","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which MHT regimen appears to drive the increased risk?",{"text":118,"@type":114},"Subgroup analyses indicate risk is confined to estrogen-progestin therapy (EPT; OR = 1.44, 95% CI: 1.26–1.64), while estrogen-only therapy (ET) showed no overall association (OR = 1.00, 95% CI: 0.91–1.10).",{"name":120,"@type":111,"acceptedAnswer":121},"How do randomized trials and observational studies differ for ET?",{"text":122,"@type":114},"For ET, randomized controlled trials suggested a protective effect (OR = 0.78, 95% CI: 0.70–0.87), whereas observational studies were neutral.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},362630,1790199274,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":56,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","AnnAls of Medicine  \n2026, Vol. 58, no. 1, 2640244  \n[https://doi.org/10.1080/07853890.2026.2640244](https://doi.org/10.1080/07853890.2026.2640244)  \nRESEARCH ARTICLE     \nRelationship between menopausal hormone therapy and incidence risk of breast cancer: systematic review and meta-analysis  \nQing Wua, Liwen Shena, Shengtao Hub, Rui Yangb , Yingnan Wangb, Dixuan Xueb, Yuchen Sunb, Haiyan Maa and Zhijun Daib  \naschool of Public Health and nursing, Hangzhou normal University, Hangzhou, Zhejiang, china; bdepartment of Breast surgery, The first Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang, china  \nABSTRACT  \nBackground: Menopausal hormone therapy (MHT) is widely prescribed for alleviating menopausal symptoms. Prior studies have mainly focused on individual hormone therapy formulations. This meta-analysis comprehensively synthesized evidence across various regimens to systematically evaluate the association between MHT and breast cancer risk.  \nMaterials and methods: We systematically searched CNKI, Wanfang, PubMed, and Web of Science from inception through August 2024. Eligible studies examining breast cancer risk following MHT were independently screened and assessed by two reviewers. The review and meta-analysis followed PRISMA guidelines.  \nResults: Thirty-four studies were included. The random-effects model showed a significant but heterogeneous overall association (OR = 1.15, 95% CI: 1.09–1.22; I² = 92.4%). Subgroup analysis identified hormone type, use status, and region as key determinants (P for interaction \u003C 0.001). Stratification by hormone type resolved much of the heterogeneity, revealing risk confined to estrogen-progestin therapy (EPT; OR = 1.44, 95% CI: 1.26–1.64), while estrogen-only therapy (ET) showed no overall association (OR = 1.00, 95% CI: 0.91–1.10). Study type, region, and sample size were significant effect modifiers. For ET, randomized controlled trials demonstrated a protective effect (OR = 0.78, 95% CI: 0.70–0.87), contrasting with neutral findings from observational studies.  \nConclusions: MHT is associated with a modest but significant increase in breast cancer risk, primarily driven by EPT. This risk was not observed with ET in observational studies, though trials suggested a protective effect. Crucially, the association shows marked geographical heterogeneity, indicating risk is modified by regimen and regional factors.  \nKEY MESSAGES  \n1. The increased breast cancer risk associated with MHT is mainly attributable to EPT, current user in Europe, with no overall risk observed for ET.  \n2. The apparent effect of ET is critically influenced by study design, with randomized trials suggesting a protective effect, in contrast to neutral findings from observational studies.  \n3. The association between MHT and breast cancer risk is not uniform but exhibits marked geographical heterogeneity, indicating that regional factors substantially modify the risk profile.  \nARTICLE HISTORY  \nReceived 19 November 2025  \nAccepted 27 February 2026  \nKEYWORDS  \nBreast cancer; menopausal; hormone therapy;  \nestrogen-progestin therapy; meta-analysis  \nCONTACT Haiyan Ma  [mahaiyan@hznu.edu.cn](mahaiyan@hznu.edu.cn)  school of Public Health and nursing, Hangzhou normal University, Hangzhou, Zhejiang 310000, china; Zhijun dai  dzj091[1@zju.edu.cn](1@zju.edu.cn)  department of Breast surgery, The first Affiliated Hospital of Zhejiang University school of Medicine, Hangzhou, Zhejiang 310000, china.  \n supplemental data for this article can be accessed online at [https://doi.org/10.1080/07853890.2026.2640244](https://doi.org/10.1080/07853890.2026.2640244) .  \n© 2026 The Author(s) . Published by informa UK limited, trading as Taylor & francis Group  \nThis is an open Access article distributed under the terms of the creative commons Attribution-noncommercial license ([http://creativecommons.org/licenses/](http://creativecommons.org/licenses/)[ ](http://creativecommons.org/licenses/)[by-nc/4.0/","cbCaicMVyR8dBxjg","https://ap.wps.com/l/cbCaicMVyR8dBxjg","pdf",2312348,"English","# Abstract\n## Background\n## Materials and methods\n## Results\n## Conclusions\n# Introduction\n## Menopausal hormone therapy and breast cancer context\n## Background evidence and prior trials","[{\"question\":\"What is the main finding about MHT and breast cancer incidence risk?\",\"answer\":\"Overall, MHT showed a significant but heterogeneous association with breast cancer risk (OR = 1.15, 95% CI: 1.09–1.22).\"},{\"question\":\"Which MHT regimen appears to drive the increased risk?\",\"answer\":\"Subgroup analyses indicate risk is confined to estrogen-progestin therapy (EPT; OR = 1.44, 95% CI: 1.26–1.64), while estrogen-only therapy (ET) showed no overall association (OR = 1.00, 95% CI: 0.91–1.10).\"},{\"question\":\"How do randomized trials and observational studies differ for ET?\",\"answer\":\"For ET, randomized controlled trials suggested a protective effect (OR = 0.78, 95% CI: 0.70–0.87), whereas observational studies were neutral.\"}]","Relationship between menopausal hormone therapy and incidence risk of breast cancer - systematic review and meta-analysis | PDF",1790148630,48,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5aa9d21f4cd404e5360f2f928a9f1a8.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/470719f392dce2082e9e7a9b466409e2.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc7b40bdbafd711ceae9e0a6f4601dad.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c21910958be5aec19a087195c5dfa2ff.webp",980,1306]